期刊
PHARMACEUTICS
卷 13, 期 7, 页码 -出版社
MDPI
DOI: 10.3390/pharmaceutics13071042
关键词
PLGA nanoparticles; neurodegenerative diseases; drug delivery; central nervous system; neuroprotective drugs
资金
- Fondation de France [00066525]
- IDEX Emergence Grant [OPE-2018-410]
- MSER fellowship (France)
- Le college des ecoles doctorales (appel doctorat interdisciplinaire 2018)
Research suggests that nanotechnology-based PLGA NPs can effectively help neuroprotective drugs pass through the blood-brain barrier for the treatment of neurodegenerative diseases.
Treatment of neurodegenerative diseases has become one of the most challenging topics of the last decades due to their prevalence and increasing societal cost. The crucial point of the non-invasive therapeutic strategy for neurological disorder treatment relies on the drugs' passage through the blood-brain barrier (BBB). Indeed, this biological barrier is involved in cerebral vascular homeostasis by its tight junctions, for example. One way to overcome this limit and deliver neuroprotective substances in the brain relies on nanotechnology-based approaches. Poly(lactic-co-glycolic acid) nanoparticles (PLGA NPs) are biocompatible, non-toxic, and provide many benefits, including improved drug solubility, protection against enzymatic digestion, increased targeting efficiency, and enhanced cellular internalization. This review will present an overview of the latest findings and advances in the PLGA NP-based approach for neuroprotective drug delivery in the case of neurodegenerative disease treatment (i.e., Alzheimer's, Parkinson's, Huntington's diseases, Amyotrophic Lateral, and Multiple Sclerosis).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据